Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia

Published:2020-12 Issue: Volume:23 Page:13-18
ISSN:2212-1099
Container-title:Value in Health Regional Issues
language:en
Short-container-title:Value in Health Regional Issues

Author:

Lasalvia Pieralessandro,Hernández Fabián,Castañeda-Cardona Camilo,Cuestas J. Andrés,Rosselli Diego

Publisher

Elsevier BV

Subject

Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Economics, Econometrics and Finance (miscellaneous)

Reference31 articles.

1. Multiple sclerosis: dealing with complex treatment decisions;Abel;Br J Nurs,2018

2. Multiple sclerosis: risk factors, prodromes, and potential causal pathways;Ramagopalan;Lancet Neurol,2010

3. GPC: Tratamiento Modificador de Enfermedad En Pacientes Con Diagnóstico de Esclerosis Múltiple. SSA-417-10,2010

4. Multiple sclerosis review;Goldenberg;P T,2012

5. Efficacy of cladribine tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study;Giovannoni;Mult Scler,2019

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review;Health Economics Review;2024-02-16

2. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom;Journal of Medical Economics;2023-12-26

3. Cost-Effectiveness of Multiple Sclerosis Therapies – A Literature Review;Acta Medica Bulgarica;2022-12-01

4. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom;PharmacoEconomics;2021-12-18

5. Real-World Comparative Cost-Effectiveness Analysis of Different Classes of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in Saudi Arabia;International Journal of Environmental Research and Public Health;2021-12-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3